According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
Other research analysts have also recently issued research reports about the stock. Needham & Company LLC reiterated a buy rating and set a $84.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Chardan Capital reiterated a buy rating and set a $72.50 price target on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Finally, William Blair reiterated a buy rating on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $78.29.
Shares of CRSP stock opened at $55.80 on Monday. Crispr Therapeutics has a 12-month low of $30.75 and a 12-month high of $74.00. The firm’s 50 day moving average is $57.02 and its 200 day moving average is $53.10. The stock has a market capitalization of $3.40 billion, a P/E ratio of 57.53 and a beta of 3.26.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $1.19. The company had revenue of $77.00 million for the quarter, compared to analysts’ expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm’s quarterly revenue was up 76900.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.92) earnings per share. On average, analysts predict that Crispr Therapeutics will post -4.61 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. lifted its stake in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares in the last quarter. Orbimed Advisors LLC purchased a new position in shares of Crispr Therapeutics during the 3rd quarter valued at $21,167,000. FMR LLC lifted its stake in shares of Crispr Therapeutics by 71.8% during the 4th quarter. FMR LLC now owns 952,369 shares of the company’s stock valued at $58,004,000 after buying an additional 398,012 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Crispr Therapeutics by 904.0% during the 4th quarter. Renaissance Technologies LLC now owns 394,564 shares of the company’s stock valued at $24,031,000 after buying an additional 355,264 shares in the last quarter. Finally, ARK Investment Management LLC lifted its stake in shares of Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after buying an additional 174,495 shares in the last quarter. Institutional investors own 51.28% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.